Table 2 Comparison between two groups with INR > 4 and ≤ 4 within 5 days of titration.
Parameter | All patients (n = 94) | Patients with INR ≤ 4 (n = 77) | Patients with INR > 4 (n = 17) | P |
|---|---|---|---|---|
Age (years) | 67.9 ± 11.6 | 68.2 ± 11.8 | 66.6 ± 11.6 | 0.942 |
≤ 50 | 7 (7.5%) | 5 (6.5%) | 2 (11.8%) | 0.886 |
51–65 | 27 (28.7%) | 24 (31.2%) | 3 (17.7%) | |
66–80 | 46 (48.9%) | 36 (46.8%) | 10 (58.8%) | |
> 80 | 14 (14.9%) | 12 (15.6%) | 2 (11.8%) | |
Weight (kg) | 61.6 ± 11.0 | 63.1 ± 11.3 | 53.8 ± 11.0 | 0.014 |
Male/female (n) | 53/41 | 46/31 | 7/10 | 0.367 |
Diabetes mellitus | 13 (13.8%) | 11 (14.3%) | 2 (11.8%) | 1.000 |
Albumin (g/L) | 37.1 ± 3.0 | 37.3 ± 3.1 | 36.0 ± 3.0 | 0.121 |
Creatinine (µmol/L) | 86.7 ± 26.9 | 83.7 ± 27.0 | 104.2 ± 26.9 | 0.233 |
Maintenance dialysis | 1 (1.1%) | 0 (0%) | 1 (5.9%) | 0.181 |
Hypertension | 36 (38.3%) | 27(35.1%) | 9 (52.9%) | 0.170 |
Congestive heart failure | 4 (4.3%) | 3 (3.9%) | 1 (5.9%) | 1.000 |
NSAIDs or alcohol | 4 (4.3%) | 4 (5.2%) | 0 (0%) | 1.000 |
Amiodarone | 3 (3.2%) | 3 (3.9%) | 0 (0%) | 1.000 |
SAMeTT2R2 | 3 (2–3) | 3 (2–3) | 3 (3–4) | 0.328 |
HAS-BLED | 2 (2–3) | 2 (2–3) | 2 (1.5–3.5) | 0.654 |
CHA2DS2-VASc | 4 (3–5) | 4 (3–5) | 4 (3–6) | 0.599 |
Get stable INR at the 5-day | 77 (81.9%) | 71 (92.2%) | 6 (35.3%) | 0.000 |
Patients with follow-up INR more than 4 times | 89 (94.7%) | 72 (93.5%) | 7 (41.9%) | 0.000 |
Times of INR follow-up | 7 (5–11) | 7 (5–11) | 5.5 (5–23.75) | 0.673 |
TTR ≥ 65% | 58 (65.2%) | 54 (70.1%) | 4 (23.5%) | 0.001 |
